Advertisement

Topics

IMRALDI®, Biogen’s Adalimumab Biosimilar Referencing Humira®, is Approved in the European Union

19:05 EDT 24 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Biogen becomes the first company with approved biosimilars for the three most prescribed anti-TNF biologic treatments in Europe. The European Commission (EC) granted a marketing authorization for IMRALDI® (also known as SB5...

Other Sources for this Article

BIOGEN EU MEDIA CONTACT:
Ryan Furby, +41 413 920 652
publicaffairs.EU@biogen.com
or
BIOGEN INVESTOR CONTACT:
Mike Hencke, +1 781-464-2442
IR@biogen.com

NEXT ARTICLE

More From BioPortfolio on "IMRALDI®, Biogen’s Adalimumab Biosimilar Referencing Humira®, is Approved in the European Union"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Cytokine Tumour Necrosis Factor (TNF)
TNF is a compound that is classified as a cytokine which plays a central role in the cellular mechanisms of apoptosis or cell death. However, there are a number of different kinds of TNF, just under twenty, but the family of molecules have very similar a...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...